PRIMARY GENERALIZED GLUCOCORTICOID RESISTANCE,

OR CHROUSOS SYNDROME

## NICOLAS C. NICOLAIDES, TOMOSHIGE KINO,

## GEORGE P. CHROUSOS, EVANGELIA CHARMANDARI

*Division of Endocrinology, Metabolism and Diabetes (N.C.N., G.P.C., E.C.), First Department of Pediatrics, University of Athens Medical School, ‘Aghia Sophia’ Children's Hospital, Athens, 11527, Greece;Division of Endocrinology and Metabolism (N.C.N., G.P.C., E.C.), Clinical Research Center, Biomedical Research Foundation of the Academy of Athens, Athens, 11527, Greece; Unit on Molecular Hormone Action (T.K.), Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, 20892, USA; and Saudi Diabetes Study Research Group (G.P.C.), King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.*

**Revised 22 December 2014**

**Author for Correspondence:**

**Nicolas C. Nicolaides, MD, PhD**

Post-doctoral Researcher

Division of Endocrinology and Metabolism

Clinical Research Center

Biomedical Research Foundation of the Academy of Athens

4 Soranou tou Efessiou Street

Athens, 11527, Greece

Tel: +30-210-6597041

Fax: +30-210-6597545

E-mail: [nnicolaides@bioacademy.gr](mailto:nnicolaides@bioacademy.gr)

**CASE REPORT**

A 35-year-old woman presented with a long-standing history of fatigue, anxiety, cystic acne and irregular menses. On physical examination, her blood pressure was 160/100mmHg and she had no stigmata of Cushing syndrome. Endocrinologic evaluation revealed increased morning plasma ACTH, serum cortisol and androstenedione concentrations, and increased urinary free cortisol (UFC) excretion.

What is the diagnosis?

How should this patient be further evaluated?

What is the appropriate treatment?

##### GLUCOCORTICOIDS

Glucocorticoids (cortisol in humans, corticosterone in most rodents) are produced by the adrenal cortex and are secreted into the systemic circulation following activation of the hypothalamic-pituitary adrenal (HPA) axis. These cholesterol-derived hormones regulate a broad spectrum of physiologic functions essential for life, such as growth, reproduction, intermediary metabolism through catabolic actions, the cardiovascular tone, behavior and cognition, and play an important role in the maintenance of resting and stress-related homeostasis (**1-4**). In addition, glucocorticoids are widely used therapeutic compounds often prescribed in the treatment of inflammatory, autoimmune and lymphoproliferative disorders because of their potent anti-inflammatory and immunomodulatory effects (**1**).

**THE GLUCOCORTICOID RECEPTOR GENE (*NR3C1*) AND PROTEIN**

At the molecular level, glucocorticoids signal through an intracellular protein, the glucocorticoid receptor (GR) (**3,** **5, 6**). The human (h) GR is a member of the steroid/thyroid/retinoic acid nuclear receptor superfamily of transcription factor proteins and functions as a ligand-dependent transcription factor that influences the transcription rate of numerous glucocorticoid target genes in a positive or negative fashion. The hGR gene (*NR3C1*) consists of 9 exons and is located on chromosome 5q31.3. Exons 2-9 constitute the protein-coding exons, whereas exon 1 consists of untranslated sequence with the transcription start site connected to multiple promoters. Alternative splicing of the hGR gene in exon 9 generates two highly homologous receptor isoforms, the hGR and hGRβ. These protein isoforms share 727 common amino acids, but then diverge, with hGR having an additional 50 amino acids and hGRβ having an additional, nonhomologous 15 amino acids. The hGR resides primarily in the cytoplasm of cells and represents the classic glucocorticoid receptor that binds natural and synthetic glucocorticoids and mediates the genomic and most of the nongenomic actions of these hormones. The hGRβ, on the other hand, does not bind glucocorticoid agonists, may or may not bind the synthetic glucocorticoid antagonist RU486, has intrinsic, hGR-independent, gene-specific transcriptional activity, and exerts a dominant negative effect upon the transcriptional activity of hGR (**3, 5-8**). Moreover, recent studies have shown that hGRβ is implicated in insulin signaling (**9**) and participates in the molecular pathogenetic mechanisms of glioma formation through regulation of β-catenin/T-cell factor/lymphoid enhancer factor (TCF/LEF) transcriptional activity (**10, 11**).


The hGR mRNA further expresses multiple isoforms by using at least 8 alternative amino-terminal translation initiation sites (**12**). All these hGR isoforms are differentially distributed in the cytoplasm and/or the nucleus in the absence of ligand, have different transcriptional activity following ligand-induced activation and display distinct transactivation or transrepression patterns on global gene expression examined by cDNA microarray analyses (**12**). Therefore, these hGR isoforms may differentially transduce the glucocorticoid signal to target tissues depending on their selective relative expression and inherent activities. Since hGRβ shares a common amino-terminal domain that contains the same translation initiation sites with the hGR, the hGRβ variant mRNA might also be translated through the same initiation sites to a similar host of hGRβ isoforms. It is likely that differential cell-specific production and functional differences might also be present between the putative hGRβ translational isoforms.

The hGR gene has at least three different promoters, A, B and C. Promoter A can be used with three untranslated exons, 1A1, 1A2 and 1A3, that contain unique promoter fragments (**13**). Therefore, the hGR gene can produce five different transcripts from different promoters that encode the same hGR proteins. Through differential use of these promoters, the expression levels of hGR proteins may vary considerably among tissues. The splice and translational hGR isoforms expressed from different promoters appear to form up to 256 different combinations of homo- and hetero-dimers with varying transcriptional activities. The marked complexity in the transcription/translation of the hGR gene enables target tissues to differentially respond to circulating glucocorticoid concentrations and accounts for the highly stochastic nature of the glucocorticoid signaling pathway (**14**).

The hGRα protein consists of four functional domains (**5**). The N-terminal or immunogenic domain (NTD) is encoded by exon 2 and represents the largest domain of the receptor containing amino acids that undergo several post-translational modifications, as well as the activation function-1 (AF-1) domain that is used by the receptor as a molecular platform for the molecular interactions with coactivators (**5**). The DNA-binding domain (DBD) is expressed by exons 3 and 4, and lies between amino acids 420 and 480. This domain consists of the characteristic motif of two zinc fingers, which facilitates the interaction between the receptor and its target DNA sequences in the promoter regions of glucocorticoid-responsive genes (**5**). The ligand-binding domain (LBD) is located at the carboxyl-terminal fragment of the receptor and corresponds to amino acids 481 to 777. Encoded by exons 5-9, this region contains amino acids responsible for the binding of the receptor to natural and synthetic glucocorticoids, for the cytoplasmic-to-nuclear translocation following ligand-induced activation of the receptor, as well as for the transactivation and interaction of the receptor with coactivator molecules (AF-2 domain) in a ligand-dependent fashion. Finally, a hinge region lies between the DBD and LBD. This protein domain provides the appropriate structural flexibility to the receptor and allows the interaction of the latter with several different glucocorticoid-responsive genes (**5**).

**GENOMIC AND NONGENOMIC hGR ACTIONS**

At the target cell, the inactivated hGR resides primarily in the cytoplasm as part of a hetero-oligomeric complex consisting of chaperone heat shock proteins (HSPs) 90, 70 and 50, immunophilins, as well as other proteins (**15**). HSP90 regulates ligand binding, as well as cytoplasmic retention of hGR by exposing the ligand-binding site and masking the two nuclear localization sequences (NLS), NL1 and NL2, which are located adjacent to the DNA-binding domain (DBD) and in the ligand-binding domain (LBD) of the receptor, respectively. Upon ligand-induced activation, the receptor undergoes a conformational change that results in dissociation from this multiprotein complex and translocation into the nucleus (**Figure 1**) (**15, 16**). Within the nucleus, the receptor binds as a dimer to tandem glucocorticoid-response elements (GREs) in the promoter regions of target genes, and regulates their expression positively or negatively depending on GRE sequence and promoter context (**17, 18**). The GRE-bound hGR stimulates the transcription of target genes by facilitating the formation of the transcription initiation complex, including the RNA polymerase II and its ancillary components (**19**). To initiate transcription, hGR uses its transcriptional activation domains, AF-1 and AF-2, as surfaces to interact with nuclear receptor coactivators and chromatin-remodeling complexes. Several coactivators form a bridge between the DNA-bound hGR and the transcription initiation complex, and facilitate the transmission of the glucocorticoid signal to the RNA polymerase II (**20-22**). These include: (1) The p300 and the homologous cAMP-responsive element-binding protein (CREB)-binding protein (CBP), which also serve as macromolecular docking “platforms” for transcription factors from several signal transduction cascades, including nuclear receptors, CREB, AP-1, NF-B, p53, Ras-dependent growth factor, and STATs. In view of their central position in many signal transduction cascades, the p300/CBP coactivators are also called co-integrators; (2) The p300/CBP-associated factor (p/CAF), which interacts with p300/CBP, but is also a broad transcription coactivator; and (3) The p160 family of coactivators, which preferentially interact with the steroid hormone receptors, and include the steroid receptor coactivator-1 (SRC-1), SRC-2 and SRC-3 (**20-22**). The hGR also interacts with several other distinct chromatin modulators through its transactivation domains, such as the mating-type switching/sucrose non-fermenting (SWI/SNF) complex and components of the vitamin D receptor-interacting protein/thyroid hormone receptor-associated protein (DRIP/TRAP) complex (**20-22**) (**Figure 1**).

**Figure 1: Genomic and nongenomic glucocorticoid actions.** Upon binding to the ligand, the activated hGR dissociates from heat shock proteins (HSPs) and translocates into the nucleus, where it homodimerizes and binds to glucocorticoid response elements (GREs) in the promoter region of target genes or interacts with other transcription factors (TFs), such as activator protein-1 (AP-1), nuclear factor-B (NF-B) and signal transducer and activator of transcription-5 (STAT5), ultimately modulating the transcriptional activity of respectively GRE- or TFRE-containing genes. In addition to the well-known genomic actions, most of the nongenomic glucocorticoid actions are mediated by membrane-bound GRs, which trigger the activation of kinase signaling pathways. GR: glucocorticoid receptor; HSP: heat shock proteins; FKBP: immunophilins; p160: nuclear receptor coactivators p160; SWI/SNF: switching/sucrose non-fermenting complex; DRIP/TRAP: vitamin D receptor-interacting protein/thyroid hormone receptor-associated protein complex; MAPK: mitogen-activated protein kinases; cPLA2α: cytosolic phospholipase A2 alpha; PI3K: phosphatidylinositol 3-kinase; eNOS: endothelial nitric oxide synthetase; NO: nitric oxide.

The ligand-activated hGR can also modulate gene expression independently of binding to GREs, by interacting possibly as a monomer with other transcription factors, such as activator protein-1 (AP-1), nuclear factor-B (NF-B), p53 and signal transducers and activators of transcription (STATs) (**23, 24**) (**Figure 1**). Therefore, hGR may affect signal transduction cascades through protein-protein interactions with specific transcription factors by influencing their ability to stimulate or inhibit the transcription rates of respective target genes. This activity may be more important than the GRE-mediated one, given that mice harboring a mutant GR, which is active in terms of protein-protein interactions but inactive in terms of transactivation via DNA, survive and procreate, in contrast to mice with a deletion of the entire GR gene that die immediately after birth from severe respiratory distress syndrome (**25**). The protein-protein interactions of GR with other transcription factors may take place on the promoters that do not contain GREs, as well as on the promoters that have both GRE(s) and responsive element(s) of transcription factors that interact with GR (“composite promoters”). Suppression of transactivation of other transcription factors through protein-protein interactions may be particularly important in suppression of immune function and inflammation by glucocorticoids (**25, 26**). Most of the effects of glucocorticoids on the immune system may be mediated by the interaction between GR and NF-B, AP-1 and STATs (**27, 28**).

Following transcriptional activation or inhibition of glucocorticoid-responsive genes, the hGR dissociates from the ligand and has a lower affinity for binding to GREs. The unliganded hGR remains within the nucleus for a considerable length of time and is then exported to the cytoplasm; both within the nucleus and within the cytoplasm the hGR may be recycled and/or degraded in the proteasome (**3, 5**) (**Figure 1**).

Although the transcriptional activity of GR is primarily governed by ligand binding, accumulating evidence suggests that post-translational modifications (PTMs) play an important additional role. These include phosphorylation, ubiquitination, acetylation and sumoylation of the receptor. These covalent changes may affect receptor stability, subcellular localization, as well as the interaction between GR and other proteins (**5**).


Further to the above-described genomic actions, mounting evidence suggests that glucocorticoids also signal within seconds or minutes. These effects are termed as “nongenomic”, since they do not require hGRα transcriptional activity. Although the underlying mechanisms are not fully understood, recent studies have demonstrated that most of the nongenomic glucocorticoid actions are triggered by membrane-bound GRs, which induce the activity of kinase signaling pathways, such as the mitogen-activated protein kinase (MAPK) or the phosphatidylinositol 3-kinase (PI3K) cascades (**29-32**) (**Figure 1**). Some representative examples of these actions are: (i) the immediate suppression of ACTH release from the anterior lobe of pituitary by glucocorticoids (**33**); (ii) the increased frequency of excitatory post-synaptic potentials in the hippocampus (**34**); (iii) the cardioprotective role of glucocorticoids through nitric oxide (NO)-mediated vasorelaxation in patients with myocardial infarction or stroke (**35**); and (iv) some immunomodulatory glucocorticoid effects via disruption of T-cell receptor signaling (**36**).

**CHROUSOS SYNDROME**

The internal equilibrium of all living organisms, termed *homeostasis*, is adequately achieved by the optimal effect of all homeostatic systems that occurs in the middle range of homeostatic activity. Too much or too little activity ultimately leads to dysfunction of homeostasis, termed *allostasis* or *cacostasis* (**37**). Alterations in any step of glucocorticoid signal transduction may cause impaired tissue sensitivity to glucocorticoids, which may present with clinical manifestations of *glucocorticoid resistance* or *glucocorticoid hypersensitivity*, conditions with significant morbidity (**38, 39**). One such condition that we have extensively investigated both at clinical and molecular level over the years is Primary Generalized Glucocorticoid Resistance or Chrousos syndrome (**40-49**).

##### Clinical Manifestations

Primary Generalized Glucocorticoid Resistance is a condition first described and elucidated by Chrousos *et al*. as a rare, familial or sporadic, genetic disorder characterized by generalized, partial, end-organ insensitivity to glucocorticoids (**43-51**). Because of the generalized glucocorticoid resistance, the glucocorticoid negative feedback inhibition at the hypothalamic and anterior pituitary levels is decreased, leading to compensatory activation of the HPA axis, inferred hypersecretion of corticotropin-releasing hormone (CRH) and arginine-vasopressin (AVP) in the hypophysial portal system and increased secretion of adrenocorticotropic hormone (ACTH) in the systemic circulation (**43-51**) (**Figure 2**). The excess ACTH secretion results in adrenocortical hyperplasia and increased secretion of cortisol and adrenal steroids with mineralocorticoid [deoxycorticosterone (DOC) and corticosterone] and/or androgenic [androstenedione, dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS)] activity (**43-51**) (**Figure 2**). It has been proposed that the term “Chrousos Syndrome” is used in place of “Primary Generalized Familial or Sporadic Glucocorticoid Resistance” (**44**).

**Figure 2: Pathophysiologic mechanisms and clinical manifestations of Chrousos syndrome.** CRH: corticotropin-releasing hormone; AVP: arginine-vasopressin; ACTH: adrenocorticotropic hormone.

The clinical presentation of Chrousos syndrome reflects the pathophysiologic alterations described above and is mainly associated with, respectively, hypertension and/or hypokalemic alkalosis and hyperandrogenism (**43-51**) (**Table 1**) (**Figure 2**). Clinical manifestations of glucocorticoid deficiency might occur, but are rare and were only reported in a young child with hypoglycemic generalized tonic-clonic seizures during the course of a febrile illness (**52**), in a newborn baby with severe hypoglycemia, excessive fatigability with feeding, increased susceptibility to infections and concurrent growth hormone deficiency (**53**), and in several adult patients with chronic fatigue. The latter might indicate inadequate glucocorticoid target tissue compensation at the central nervous system (CNS) and/or the skeletal muscles by the increased circulating cortisol concentrations (**43-51**). Clinical manifestations of androgen excess include ambiguous genitalia in a karyotypic female at birth and gonadotropin-independent precocious puberty in children of either gender; acne, hirsutism and decreased fertility in both sexes; male-pattern hair loss, menstrual irregularities and oligo-anovulation in females; and oligospermia in males (**Table 1**). The impaired fertility in both sexes has been attributed in part to the feedback inhibition of gonadotropin secretion by the elevated androgen concentrations, while the profound anxiety observed in some subjects is probably due to compensatory increases in hypothalamic CRH and AVP secretion. The latter might also predispose the patients to the development of an ACTH-secreting pituitary adenoma. Finally, the elevated circulating ACTH concentrations may be responsible for the observed growth of intra-testicular adrenal rests and oligospermia (**43-51**).

TABLE 1: Clinical Manifestations and Diagnostic Evaluation of Chrousos Syndrome \*

**Clinical Presentation**

Apparently normal glucocorticoid function in most cases

Asymptomatic

Hypoglycemia, chronic fatigue (glucocorticoid deficiency?)

Mineralocorticoid excess

Hypertension

Hypokalemic alkalosis

Androgen excess

Children: Ambiguous genitalia at birth\*\*, clitoromegaly, premature adrenarche, gonadotropin-independent precocious puberty

Females: Acne, hirsutism, male-pattern hair loss, menstrual irregularities, oligo-anovulation, hypofertility

Males: Acne, hirsutism, oligospermia, adrenal rests in the testes, hypofertility

Increased HPA axis activity (CRH/AVP and ACTH hypersecretion)

Anxiety

Adrenal rests (oligospermia)

Pituitary corticotropinoma

Diagnostic Evaluation

Absence of clinical features of Cushing syndrome

Normal or elevated plasma ACTH concentrations

Elevated serum or plasma cortisol concentrations

Increased 24-hour urinary free cortisol excretion

Normal circadian and stress-induced pattern of cortisol and ACTH secretion

Resistance of the HPA axis to dexamethasone suppression

Thymidine incorporation assays: Increased resistance to dexamethasone-induced suppression of phytohemaglutinin-stimulated thymidine incorporation compared to control subjects

Dexamethasone-binding assays: Decreased concentration or affinity of the glucocorticoid receptor for the ligand compared to control subjects

Molecular studies: Mutations/deletions of the glucocorticoid receptor; functional studies of mutant receptors

\* Modified from Reference 44.

\*\* This is the only case of ambiguous genitalia documented in a child with 46,XX karyotype who also harbored a heterozygous mutation of the 21-hydroxylase gene.

The clinical spectrum of Chrousos syndrome is broad, ranging from most severe to mild forms, and a number of patients may be asymptomatic, displaying biochemical alterations only (**43-51**) (**Table 1**). This variable clinical phenotype is due to variations in the tissue sensitivity of the glucocorticoid, mineralocorticoid and/or androgen receptor signaling pathways; variations in the activity of key hormone-inactivating or -activating enzymes, such as the 11β-hydroxysteroid dehydrogenase (**54**) and 5-reductase (**55**); and other genetic or epigenetic factors, such as the presence of insulin resistance and visceral obesity (**51**).


***Molecular Mechanisms***

The molecular basis of Chrousos syndrome has been ascribed primarily to mutations in the hGR gene, which impair the molecular mechanisms of hGR action and decrease tissue sensitivity to glucocorticoids. The pathologic hGR gene mutations causing Chrousos syndrome that have been reported to date are shown in **Table 2** (**50, 52, 53,** **56-70**) and **Figure 3**. Eleven out of 15 of these mutations are heterozygous (4 are homozygous), while all mutations partially inactivate hGR function. Although studies of GR knock-out mice suggested that complete loss-of-function of the GR is incompatible with extrauterine life (**71**), one out of 15 of the mutations completely inactivated hGR function (**53**). The first describedhGR gene mutation was a homozygotic adenine to thymine substitution at nucleotide position 1922, which resulted in substitution of aspartic acid to valine at amino acid residue 641 (**50**). *In vitro* studies showed that the mutant receptor hGRαD641V demonstrated decreased ability to transactivate glucocorticoid-responsive genes, had lower affinity for the ligand, showed delayed nuclear translocation when exposed to ligand and interacted with the glucocorticoid receptor interacting protein 1 (GRIP1) less effectively (**50**).

**TABLE 2: Mutations of the Human Glucocorticoid Receptor Gene Causing Chrousos Syndrome**\*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author (Reference)** | **cDNA** | **Amino acid** | **Molecular Mechanisms** | **Genotype** | **Phenotype** |
| Chrousos et al. (**50**)  Hurley et al. (**57**) | 1922 (A®T) | 641 (D®V) | Transactivation ¯  Affinity for ligand ¯ (x 3)  Nuclear translocation: 22 min  Abnormal interaction with GRIP1 | Homozygous | Hypertension  Hypokalemic alkalosis |
|  |  |  |  |  |  |
| Karl et al. (**58**) | 4 bp deletion in exon-intron 6 |  | hGRα number: 50% of control  Inactivation of the affected allele | Heterozygous | Hirsutism  Male-pattern hair-loss  Menstrual irregularities |
|  |  |  |  |  |  |
| Malchoff et al. (**59**) | 2185 (G®A) | 729 (V®I) | Transactivation ¯  Affinity for ligand ¯ (x 2)  Nuclear translocation: 120 min  Abnormal interaction with GRIP1 | Homozygous | Precocious puberty  Hyperandrogenism |
|  |  |  |  |  |  |
| Karl et al. (**56**)  Kino et al. (**60**) | 1676 (T®A) | 559 (I®N) | Transactivation ¯  Decrease in hGR binding sites  Transdominance (+)  Nuclear translocation: 180 min  Abnormal interaction with GRIP1 | Heterozygous | Hypertension  Oligospermia  Infertility |
|  |  |  |  |  |  |
| Ruiz et al. (**61**)  Charmandari et al. (**66**) | 1430 (G®A) | 477 (R®H) | Transactivation ¯  No DNA binding  Nuclear translocation: 20 min | Heterozygous | Hirsutism  Fatigue  Hypertension |
|  |  |  |  |  |  |
| Ruiz et al. (**61**)  Charmandari et al. (**66**) | 2035 (G®A) | 679 (G®S) | Transactivation ¯  Affinity for ligand ¯ (x 2)  Nuclear translocation: 30 min  Abnormal interaction with GRIP1 | Heterozygous | Hirsutism  Fatigue  Hypertension |
|  |  |  |  |  |  |
| Mendonca et al. (**62**) | 1712 (T®C) | 571 (V®A) | Transactivation ¯  Affinity for ligand ¯ (x 6)  Nuclear translocation: 25 min  Abnormal interaction with GRIP1 | Homozygous | Ambiguous genitalia  Hypertension  Hypokalemia  Hyperandrogenism |
|  |  |  |  |  |  |
| Vottero et al. (**63**) | 2241 (T®G) | 747 (I®M) | Transactivation ¯  Transdominance (+)  Affinity for ligand ¯ (x 2)  Nuclear translocation ¯  Abnormal interaction with GRIP1 | Heterozygous | Cystic acne  Hirsutism  Oligo-amenorrhea |
|  |  |  |  |  |  |
| Charmandari et al. (**65**) | 2318 (T®C) | 773 (L®P) | Transactivation ¯  Transdominance (+)  Affinity for ligand ¯ (x 2.6)  Nuclear translocation: 30 min  Abnormal interaction with GRIP1 | Heterozygous | Fatigue  Anxiety  Acne  Hirsutism  Hypertension |
|  |  |  |  |  |  |
| Charmandari et al. (**67**) | 2209 (T®C) | 737 (F®L) | Transactivation ¯  Transdominance (time-dependent) (+)  Affinity for ligand ¯ (x 1.5)  Nuclear translocation: 180 min | Heterozygous | Hypertension  Hypokalemia |
|  |  |  |  |  |  |
| McMahon et al. (**53**) | 2 bp deletion  at nt 2318-9 | 773 | Transactivation ¯  Affinity for ligand: absent  No suppression of IL-6 | Homozygous | Hypoglycemia  Fatigability with feeding  Hypertension |
|  |  |  |  |  |  |
| Nader et al. (**52**) | 2141 (G®A) | 714 (R®Q) | Transactivation ¯  Transdominance (+)  Affinity for ligand ¯ (x 2)  Nuclear translocation ¯  Abnormal interaction with GRIP1 | Heterozygous | Hypoglycemia  Hypokalemia  Hypertension  Mild clitoromegaly  Advanced bone age  Precocious pubarche |
|  |  |  |  |  |  |
| Zhu Hui-juan et al. (**68**) | 1667 (G®T) | 556 (T®I) | Not studied yet | Heterozygous | Adrenal incidentaloma |
|  |  |  |  |  |  |
| Roberts et al. (**69**) | 1268 (T®C) | 423 (V®A) | Transactivation ¯  Affinity for ligand: N  No DNA binding  Nuclear translocation: 35 min  Interaction with GRIP1: N | Heterozygous | Fatigue  Anxiety  Hypertension |
|  |  |  |  |  |  |
| Nicolaides et al. (**70**) | 1724 (T®G) | 575 (V®G) | Transactivation ¯  Transrepression   Affinity for ligand ¯ (x 2)  Nuclear translocation ¯  Abnormal interaction with GRIP1 | Heterozygous | Melanoma  Asymptomatic daughters |

\* Modified from Reference 44.

**Figure 3: Location of the known mutations of the glucocorticoid receptor (hGR) gene.** Mutations in the upper panel are located in the LBD of the receptor, while V423A and R477H are located in the DBD of the receptor. Modified from Reference **49**.

The molecular mechanisms through which these various natural hGR mutfected glucocorticoid signal transduction were systematically investigated in all reported cases with the condition. These mechanisms included: i) the transcriptional activity of the mutant receptors; ii) the ability of the heterozygous mutant receptors to exert a dominant negative effect upon the wild-type receptor; iii) the concentrations and affinity of the mutant receptors for the ligand; iv) the subcellular localization of the mutant receptors and their nuclear following exposure to the ligand; v) the ability of the mutant receptors to bind to GREs; vi) the interaction of the mutant receptors with the glucocorticoid receptor-interacting protein 1 (GRIP1) coactivator, that belongs to the p160 family of nuclear receptor coactivators and plays an important role in hGR-mediated transactivation of glucocorticoid-responsive genes; vii) the motility of the mutant receptors inside the nucleus; viii) the ability of the mutant receptors to transrepress the NF-κB signaling pathway; and ix) structural biology studies (**50, 52, 53,** **56-70**).

The molecular defects that have been elucidated in cases with Chrousos syndrome are summarized in **Table 2**. Compared with the wild-type receptor, all mutant receptors demonstrated variable reduction in their ability to transactivate glucocorticoid-responsive genes following exposure to dexamethasone, with the most severe impairment observed in the cases of V423A, R477H, I559N, V571A and D641V mutations (**50, 52, 53,** **56-70**). Furthermore, the mutant receptors hGRI559N, hGRR714Q, hGRF737L, hGRI747M and hGRL773P exerted a dominant negative effect upon the wild-type receptor, which might have contributed to manifestation of the disease at the heterozygote state (**52,** **56, 60, 63, 65, 67**). All mutant receptors in which the mutations were located in the LBD of the receptor showed a variable reduction in their affinity for the ligand, with the most severe reduction observed in the cases of I559N, I747M and V571A mutations (**50, 52, 53,** **56-70**). The only two mutant receptors that demonstrated normal affinity for the ligand were the hGRV423A and the hGRR477H, in which the mutations were located at the DBD (**66, 69**).

In subcellular localization and nuclear translocation studies, the pathologic mutant receptors were observed primarily in the cytoplasm of cells in the absence of ligand, except for the hGRV729I and hGRF737L receptors, which were localized both in the cytoplasm and nucleus of cells. Exposure to dexamethasone induced a slow translocation of the mutant receptors into the nucleus, which ranged from 20 min (R477H) to 180 min (I559N and F737L) compared with the wild-type hGR, which required only 12 min for complete translocation (**50, 52, 53,** **56-70**). These findings suggest that all hGR mutations affect the nucleocytoplasmic shuttling of the receptor, probably through impairment of the nuclear localization signal (NL)-1 and/or NL2 functions (**72**). Interestingly, the mutant receptor hGRV423A also showed delayed cytoplasmic-to-nuclear translocation upon exposure to dexamethasone, compared with the wild-type hGR. Although this mutation was located in the first zinc finger of the DBD of the receptor, it indirectly affected the function of NL1 through R477 leading to delayed cytoplasmic-to-nuclear translocation (**69**).

All mutant receptors in which the mutations were located in the LBD preserved their ability to bind to DNA (**50, 52, 53,** **56-70**). The only two mutant receptors that failed to bind to DNA were the hGRR477H, in which the mutation was located at the C-terminal zinc finger of the DBD, and the hGRV423A, in which the point substitution was found in the first zinc finger of the DBD of the receptor (**66, 69**). A major function of the C-terminal zinc finger of the DBD of hGR  is to contribute to receptor homodimerization, a prerequisite for potent receptor binding to GREs and efficient transactivation of glucocorticoid-responsive genes (**73**). All mutant receptors except hGRR477H and hGRV423A displayed an abnormal interaction with the GRIP1 (SRC-2) coactivator *in vitro* (**50, 52, 53,** **56-70**). Moreover, all mutant receptors had dynamic motility defects inside the nucleus of living cells, possibly caused by their inability to properly interact with key partner nuclear molecules of the transcription initiation complex necessary for full activation of glucocorticoid-responsive genes (**74**). Furthermore, using new-applied reporter assays, we investigated the ability of the two recently described mutant receptors hGRαV423A and hGRαV575G to transrepress the NF-κB signaling pathway. We showed that only the hGRαV575G significantly increased the transrepression of the NF-κB signaling pathway (**69, 70**).

Structural biology studies were conducted for the mutations R714Q, V423A and V575G in an attempt to explain how alterations in the structure of the mutant receptors may cause generalized glucocorticoid resistance (**52,** **69, 70**). The substitution of arginine (R) by glutamine (Q) in the LBD of hGRαR714Q broke the salt bridge with E662 and formed a stable new salt bridge with R704 of helix 9. This alteration displaced helix 10 from its former salt bridge constraint and caused further conformational changes of the ligand-binding pocket. Furthermore, the R714Q destabilized the AF2 domain, leading to impaired interaction of the mutant receptor with the GRIP1 coactivator (**52**). In the case of V423A mutation, the substitution of valine (V) to alanine (A) destroyed the protective environment created by the hydrophobic valine for the four zinc-binding cysteines (C421, C424, C438 and C441) and permitted molecules of water to diffuse into the zinc-binding region of the receptor, therefore reducing the DNA-binding ability of the hGRαV423A (**69**). Finally, the replacement of valine (V) by glycine at amino acid position 575 in the LBD of the receptor destroyed the two noncovalent bonds between valine and the second and third leucine of the LXXLL motif of the GRIP1 coactivator, ultimately leading to glucocorticoid resistance (**70**).

***Clinical Evaluation of the Patients***

The first step in evaluating a patient with suspected Chrousos syndrome is to obtain a complete personal and family history, with particular attention to evidence suggesting hyperactivity of the HPA axis and ACTH hypersecretion-related pathology. In addition, any evidence suggesting possible CNS dysfunction, such as headaches, visual impairment or seizures, should be noted. In female subjects, the regularity of menstrual cycles should be documented. In children and adolescents, growth and sexual maturation should be evaluated carefully, given that progressive hyperandrogenism is almost invariably associated with an increased growth velocity, an advanced bone age and changes in pubertal development.

The physical examination should include an assessment for signs of hyperandrogenism and/or virilization, such as acne, hirsutism, pubic and axillary hair development, male-pattern hair loss and clitoromegaly. Hirsutism should be assessed using the Ferriman-Gallwey score (**75**), while pubic hair development should be classified according to Tanner (**76, 77**). Arterial blood pressure should be recorded and preferably monitored over a 24-hour period. All subjects should be screened for signs suggestive of Cushing syndrome and undergo a complete neurologic examination.

***Endocrinologic Evaluation of the Patients***

The concentrations of plasma ACTH, renin activity (recumbent and upright) and aldosterone, as well as those of serum cortisol, testosterone, androstenedione, DHEA and DHEAS should be recorded in the morning. Determination of the 24-hour urinary free cortisol (UFC) excretion on 2 or 3 consecutive days is central to the diagnosis, given that patients with the condition demonstrate increased 24h UFC excretion in the absence of clinical manifestations suggestive of hypercortisolism. Plasma ACTH concentrations may be normal or high. However, the circadian pattern of ACTH and cortisol secretion and their responsiveness to stressors are preserved, albeit at higher concentrations.

The responsiveness of the HPA axis to exogenous glucocorticoids should also be tested with dexamethasone suppression testing. Increasing doses of dexamethasone should be given orally at midnight every other day, and a serum sample should be drawn at 0800h the following morning for determination of serum cortisol and dexamethasone concentrations. Affected subjects demonstrate resistance of the HPA axis to dexamethasone suppression, which may vary depending on the severity of the condition. The concurrent measurement of serum dexamethasone concentrations is suggested in order to exclude the possibility of increased metabolic clearance or decreased absorption of this medication.

***Cellular and Molecular Studies in the Patients***

Thymidine incorporation assays and dexamethasone-binding assays on peripheral blood mononuclear cells in association with sequencing of the hGR gene are necessary to confirm the diagnosis and to provide genetic counseling (**50, 52, 53,** **56-70**) (**Table 1**). In affected subjects, the thymidine incorporation assays reveal resistance to dexamethasone-induced suppression of phytohemaglutinin-stimulated thymidine incorporation, while the dexamethasone-binding assays often show decreased affinity of the hGR receptor for the ligand compared to control subjects. Sequencing of the coding region of the hGR gene, including the intron/exon junctions, will reveal mutations or deletions in most (**50, 52, 53,** **56-70**) but not all (**78**) cases. Finally, once the sequence defect is determined, its adverse effects on receptor function should be confirmed using *in vitro* mutagenesis and standardized assays that examine the ability of the mutant receptor to transactivate glucocorticoid-responsive genes.

***Management of the Patients***

The aim of treatment in Chrousos syndrome is to suppress the excess secretion of ACTH, thereby suppressing the increased production of adrenal steroids with mineralocorticoid and/or androgenic activity. Treatment involves administration of high doses of mineralocorticoid-sparing synthetic glucocorticoids, which activate the mutant and/or wild-type hGR and suppress the endogenous secretion of ACTH in affected subjects (**43-51**). Adequate suppression of the HPA axis is of particular importance in cases of severe impairment of hGR  action, given that long-standing corticotroph hyperstimulation in association with decreased glucocorticoid negative feedback inhibition at the hypothalamic and pituitary levels may lead to the development of an ACTH-secreting adenoma (**56**). Long-term dexamethasone treatment should be carefully titrated according to the clinical manifestations and biochemical profile of the affected subjects (**43-51**).

**Conclusions and Recommendations**

##### The glucocorticoid receptor is a ubiquitously expressed intracellular, ligand-dependent transcription factor, which mediates the action of glucocorticoids and influences physiologic functions essential for life. Mutations in the hGR gene impair one or more of the molecular mechanisms of glucocorticoid action, thereby altering tissue sensitivity to glucocorticoids. A consequent increase in the activity of the HPA axis compensates for the reduced sensitivity of peripheral tissues to glucocorticoids at the expense of ACTH hypersecretion-related pathology. The variable clinical phenotype of Chrousos syndrome, including chronic fatigue, mild hypertension and hyperandrogenism, in association with the difficulties encountered in establishing the correct diagnosis may account for the low reported prevalence of the condition, given that many cases may be unrecognized and misclassified. We recommend screening with 24h UFC excretion and sequencing of the hGR gene in patients with manifestations of mineralocorticoid and androgen excess (hypertension, hirsutism, menstrual irregularities, oligo-anovulation, impaired fertility), in whom detailed investigations fail to reveal an underlying etiology.

##### 

REFERENCES

1. Kino T, Chrousos GP. Glucocorticoid effects on gene expression. In Handbook of Stress and the Brain, T. Steckler, N. H. Kalin, J. M. H. M. Reul, Eds. (Elsevier, Amsterdam, 2005), pp. 295–311.
2. Chrousos GP, Charmandari E, Kino T. Glucocorticoid action networks–an introduction to systems biology. J. Clin. Endocrinol. Metab. 2004; 89, 563–564.
3. Chrousos GP. The glucocorticoid receptor gene, longevity, and the complex disorders of Western societies. Am. J. Med. 2004; 117, 204–207.
4. Galon J, Franchimont D, Hiroi N, Frey G, Boettner A, Ehrhart-Bornstein M, O'Shea JJ, Chrousos GP, Bornstein SR. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 2002; 16(1):61-71.
5. Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E. The human glucocorticoid receptor: molecular basis of biologic function. Steroids. 2010; 75(1): 1-12.
6. Duma D, Jewell CM, Cidlowski JA. Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. J Steroid Biochem Mol Biol. 2006; 102(1-5): 11-21.
7. Kino T, Manoli I, Kelkar S, Wang Y, Su YA, Chrousos GP. Glucocorticoid receptor (GR) β has intrinsic, GR-independent transcriptional activity. Biochem Biophys Res Commun. 2009; 381(4): 671-5.
8. Oakley RH, Jewell CM, Yudt MR, Bofetiado DM, Cidlowski JA. The dominant negative activity of the human glucocorticoid receptor β isoform. Specificity and mechanisms of action. J Biol Chem. 1999; 274(39): 27857-66.
9. Stechschulte LA, Wuescher L, Marino JS, Hill JW, Eng C, Hinds TD Jr. Glucocorticoid receptor β stimulates Akt1 growth pathway by attenuation of PTEN. J Biol Chem. 2014; 289: 17885-94.
10. Yin Y, Zhang X, Li Z, Deng L, Jiao G, Zhang B, Xie P, Mu H, Qiao W, Zou J. Glucocorticoid receptor β regulates injury-mediated astrocyte activation and contributes to glioma pathogenesis via modulation of β-catenin/TCF transcriptional activity. Neurobiol Dis. 2013; 59: 165-176.
11. Wang Q, Lu PH, Shi ZF, Xu YJ, Xiang J, Wang YX, Deng LX, Xie P, Yin Y, Zhang B, Mu HJ, Qiao WZ, Cui H, Zou J. Glucocorticoid Receptor β Acts as a Co-activator of T-Cell Factor 4 and Enhances Glioma Cell Proliferation. Mol Neurobiol*.* 2014. [Epub ahead of print].
12. Lu NZ, Cidlowski JA. Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol Cell 2005; 18: 331-342.
13. Breslin MB, Geng D, Vedeckis WV. Multiple promoters exist in the human GR gene, one of which is activated by glucocorticoids. Mol Endocrinol 2001; 15: 1381-1395.
14. Chrousos GP, Kino T. Intracellular glucocorticoid signaling: a formerly simple system turns stochastic. Sci STKE. 2005; 2005(304): pe48.
15. Pratt WB. The role of heat shock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor. J Biol Chem. 1993; 268(29): 21455-8.
16. Terry LJ, Shows EB, Wente SR. Crossing the nuclear envelope: hierarchical regulation of nucleocytoplasmic transport. Science. 2007; 318(5855): 1412-6.
17. Bamberger CM, Schulte HM, Chrousos GP. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev. 1996; 17(3): 245-61.
18. Schaaf MJ, Cidlowski JA. Molecular mechanisms of glucocorticoid action and resistance. J Steroid Biochem Mol Biol. 2002; 83(1-5): 37-48.
19. Beato M, Sanchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev 1996; 17: 587-609.
20. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev. 1999; 20(3): 321-44.
21. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell. 2002; 108: 465-474.
22. Auboeuf D, Honig A, Berget SM, O'Malley BW. Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science. 2002; 298: 416-419.
23. Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, Herrlich P. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell. 1990; 62(6): 1189-204.
24. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS Jr. Characterization of mechanisms involved in transrepression of NF-B by activated glucocorticoid receptors. Mol Cell Biol. 1995; 15(2): 943-53.
25. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, Schutz G. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998; 93: 531-541.
26. Reichardt HM, Tuckermann JP, Gottlicher M, Vujic M, Weih F, Angel P, Herrlich P, Schutz G. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J 2001; 20: 7168-7173.
27. Barnes PJ, Karin M. Nuclear factor-B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071.
28. Didonato JA, Saatcioglu F, Karin M. Molecular mechanisms of immunosuppression and anti-inflammatory activities by glucocorticoids. Am J Respir Crit Care Med 1996; 154: S11-15.
29. Ayroldi E, Cannarile L, Migliorati G, Nocentini G, Delfino DV, Riccardi C. Mechanismsof theanti-inflammatoryeffectsofglucocorticoids*:* genomicand nongenomicinterferencewithMAPKsignalingpathways*.* FASEB J. 2012; 26: 4805-4820.
30. Song IH, Buttgereit F. Non-genomic glucocorticoid effects to provide the basis for new drug developments. Mol Cell Endocrinol. 2006; 246: 142–146.
31. Lee SR, Kim HK, Youm JB, Dizon LA, Song IS, Jeong SH, Seo DY, Ko KS, Rhee BD, Kim N, Han J. Non-genomiceffectofglucocorticoidsoncardiovascular system*.* Pflugers Arch. 2012; 464: 549-559.
32. Bellavance MA, Rivest S. The neuroendocrine control of the innate immune system in health and brain diseases. Immunol Rev. 2012; 248: 36-55.
33. Hinz B, Hirschelmann R. Rapid non-genomic feedback effects of glucocorticoids on CRF-induced ACTH secretion in rats. Pharm Res*.* 2000; 17: 1273-1277.
34. Karst H, Berger S, Turiault M, Tronche F, Schütz G, Joëls M. Mineralocorticoid receptors are indispensable for nongenomic modulation of hippocampal glutamate transmission by corticosterone. Proc Natl Acad Sci USA 2005; 102: 19204-19207.
35. Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier JC, Rebsamen MC, Hsieh CM, Chui DS, Thomas KL, Prorock AJ, Laubach VE, Moskowitz MA, French BA, Ley K, Liao JK. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med. 2002; 8: 473-479.
36. Löwenberg M, Verhaar AP, Bilderbeek J, Marle J, Buttgereit F, Peppelenbosch MP, van Deventer SJ, Hommes DW. Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN.EMBO Rep 2006;7:1023-1029.
37. Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol 2009; 5: 374-381.
38. Chrousos GP. Hormone Resistance and Hypersensitivity States. In: Modern Endocrinology Series. Chrousos GP, Olefsky JM, Samols E. (eds). Lippincott, Williams & Wilkins; Philadelphia, PA, 2002; page 542.
39. Kino T, De Martino MU, Charmandari E, Mirani M, Chrousos GP. Tissue glucocorticoid resistance/hypersensitivity syndromes. J Steroid Biochem Mol Biol. 2003; 85(2-5): 457-467.
40. Kino T, Vottero A, Charmandari E, Chrousos GP. Familial/sporadic glucocorticoid resistance syndrome and hypertension. Ann N Y Acad Sci. 2002; 970: 101-11.
41. Charmandari E, Kino T, Chrousos GP. Familial/sporadic glucocorticoid resistance: clinical phenotype and molecular mechanisms. Ann N Y Acad Sci. 2004; 1024: 168-81.
42. Charmandari E, Kino T. Novel causes of generalized glucocorticoid resistance. Horm Metab Res. 2007; 39(6): 445-50.
43. Charmandari E, Kino T, Ichijo T, Chrousos GP. Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder. J Clin Endocrinol Metab. 2008; 93(5): 1563-72.
44. Charmandari E, Kino T. Chrousos syndrome: a seminal report, a phylogenetic enigma and the clinical implications of glucocorticoid signalling changes. Eur J Clin Invest. 2010; 40: 932-942.
45. Charmandari E. Primary generalized glucocorticoid resistance and hypersensitivity. Horm Res Paediatr. 2011; 76: 145-155.
46. Chrousos G. Q&A: primary generalized glucocorticoid resistance. BMC Med. 2011; 9: 27.
47. Charmandari E. Primary generalized glucocorticoid resistance and hypersensitivity: the end-organ involvement in the stress response. Sci Signal. 2012; 5: pt5.
48. Charmandari E, Kino T, Chrousos GP. Primary generalized familial and sporadic glucocorticoid resistance (Chrousos syndrome) and hypersensitivity. Endocr Dev. 2013; 24: 67-85.
49. Nicolaides NC, Charmandari E, Chrousos GP, Kino T. Recent advances in the molecular mechanisms determining tissue sensitivity to glucocorticoids: novel mutations, circadian rhythm and ligand-induced repression of the human glucocorticoid receptor. BMC Endocr Disord. 2014; 14: 71.
50. Chrousos GP, Vingerhoeds A, Brandon D, Eil C, Pugeat M, DeVroede M, Loriaux DL, Lipsett MB. Primary cortisol resistance in man. A glucocorticoid receptor-mediated disease. J Clin Invest. 1982; 69(6): 1261-9.
51. Chrousos GP, Detera-Wadleigh SD, Karl M. Syndromes of glucocorticoid resistance. Ann Intern Med. 1993; 119(11): 1113-24.
52. Nader N, Bachrach BE, Hurt DE, Gajula S, Pittman A, Lescher R, Kino T. A novel point mutation in the helix 10 of the human glucocorticoid receptor causes Generalized Glucocorticoid Resistance by disrupting the structure of the ligand-binding domain. J Clin Endocrinol Metab. 2010; 95(5): 2281-5.
53. McMahon SK, Pretorius CJ, Ungerer JP, Salmon NJ, Conwell LS, Pearen MA, Batch JA. Neonatal complete generalized glucocorticoid resistance and growth hormone deficiency caused by a novel homozygous mutation in Helix 12 of the ligand binding domain of the glucocorticoid receptor gene (NR3C1). J Clin Endocrinol Metab. 2010; 95(1): 297-302.
54. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM. 11β-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev. 2004; 25(5): 831-66.
55. Wilson JD, Griffin JE, Russell DW. Steroid 5-reductase 2 deficiency. Endocr Rev. 1993; 14(5): 577-93.
56. Karl M, Lamberts SW, Koper JW, Katz DA, Huizenga NE, Kino T, Haddad BR, Hughes MR, Chrousos GP. Cushing's disease preceded by generalized glucocorticoid resistance: clinical consequences of a novel, dominant-negative glucocorticoid receptor mutation. Proc Assoc Am Physicians. 1996; 108(4): 296-307.
57. Hurley DM, Accili D, Stratakis CA, Karl M, Vamvakopoulos N, Rorer E, Constantine K, Taylor SI, Chrousos GP. Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin Invest. 1991; 87(2): 680-686.
58. Karl M, Lamberts SW, Detera-Wadleigh SD, Encio IJ, Stratakis CA, Hurley DM, Accili D, Chrousos GP. Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene. J Clin Endocrinol Metab. 1993; 76(3): 683-689.
59. Malchoff DM, Brufsky A, Reardon G, McDermott P, Javier EC, Bergh CH, Rowe D, Malchoff CD. A mutation of the glucocorticoid receptor in primary cortisol resistance. J Clin Invest. 1993; 91(5): 1918-1925.
60. Kino T, Stauber RH, Resau JH, Pavlakis GN, Chrousos GP. Pathologic human GR mutant has a transdominant negative effect on the wild-type GR by inhibiting its translocation into the nucleus: importance of the ligand-binding domain for intracellular GR trafficking. J Clin Endocrinol Metab. 2001; 86(11): 5600-5608.
61. Ruiz M, Lind U, Gafvels M, Eggertsen G, Carlstedt-Duke J, Nilsson L, Holtmann M, Stierna P, Wikstrom AC, Werner S. Characterization of two novel mutations in the glucocorticoid receptor gene in patients with primary cortisol resistance. Clin Endocrinol (Oxf). 2001; 55(3): 363-371.
62. Mendonca BB, Leite MV, de Castro M, Kino T, Elias LL, Bachega TA, Arnhold IJ, Chrousos GP, Latronico AC. Female pseudohermaphroditism caused by a novel homozygous missense mutation of the GR gene. J Clin Endocrinol Metab. 2002; 87(4): 1805-1809.
63. Vottero A, Kino T, Combe H, Lecomte P, Chrousos GP. A novel, C-terminal dominant negative mutation of the GR causes familial glucocorticoid resistance through abnormal interactions with p160 steroid receptor coactivators. J Clin Endocrinol Metab. 2002; 87(6): 2658-2667.
64. Charmandari E, Kino T, Vottero A, Souvatzoglou E, Bhattacharyya N, Chrousos GP. Natural glucocorticoid receptor mutants causing generalized glucocorticoid resistance: Molecular genotype, genetic transmission and clinical phenotype. J Clin Endocrinol Metab. 2004; 89(4): 1939-49.
65. Charmandari E, Raji A, Kino T, Ichijo T, Tiulpakov A, Zachman K, Chrousos GP. A novel point mutation in the ligand-binding domain (LBD) of the human glucocorticoid receptor (hGR) causing generalized glucocorticoid resistance: the importance of the C terminus of hGR LBD in conferring transactivational activity. J Clin Endocrinol Metab. 2005; 90(6): 3696-705.
66. Charmandari E, Kino T, Ichijo T, Zachman K, Alatsatianos A, Chrousos GP. Functional characterization of the natural human glucocorticoid receptor (hGR) mutants hGRR477H and hGRG679S associated with generalized glucocorticoid resistance. J Clin Endocrinol Metab. 2006; 91(4):1535-43.
67. Charmandari E, Kino T, Ichijo T, Jubiz W, Mejia L, Zachman K, Chrousos GP. A novel point mutation in helix 11 of the ligand-binding domain of the human glucocorticoid receptor gene causing generalized glucocorticoid resistance. J Clin Endocrinol Metab. 2007; 92(10)*:* 3986-90*.*
68. Zhu HJ, Dai YF, Wang O, Li M, Lu L, Zhao WG, Xing XP, Pan H, Li NS, Gong FY. Generalized glucocorticoid resistance accompanied with an adrenocortical adenoma and caused by a novel point mutation of human glucocorticoid receptor gene. Chin Med J (Engl) 2011; 124: 551-555.
69. Roberts ML, Kino T, Nicolaides NC, Hurt DE, Katsantoni E, Sertedaki A, Komianou F, Kassiou K, Chrousos GP, Charmandari E. A novel point mutation in the DNA-binding domain (DBD) of the human glucocorticoid receptor causes primary generalized glucocorticoid resistance by disrupting the hydrophobic structure of its DBD. J Clin Endocrinol Metab. 2013; 98: E790-E795.
70. Nicolaides NC, Roberts ML, Kino T, Braatvedt G, Hurt DE, Katsantoni E, Sertedaki A, Chrousos GP, Charmandari E. A novel point mutation of the human glucocorticoid receptor gene causes primary generalized glucocorticoid resistance through impaired interaction with the LXXLL motif of the p160 coactivators: dissociation of the transactivating and transreppressive activities. J Clin Endocrinol Metab. 2014; 99: E902-E907.
71. Cole TJ, Blendy JA, Monaghan AP, Krieglstein K, Schmid W, Aguzzi A, Fantuzzi G, Hummler E, Unsicker K, Schutz G. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev. 1995; 9(13): 1608-21.
72. Savory JG, Hsu B, Laquian IR, Giffin W, Reich T, Hache RJ, Lefebvre YA. Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid receptor. Mol Cell Biol. 1999; 19(2): 1025-37.
73. Dahlman-Wright K, Wright A, Gustafsson JA, Carlstedt-Duke J. Interaction of the glucocorticoid receptor DNA-binding domain with DNA as a dimer is mediated by a short segment of five amino acids. J Biol Chem. 1991; 266(5): 3107-12.
74. Kino T, Liou SH, Charmandari E, Chrousos GP. Glucocorticoid receptor mutants demonstrate increased motility inside the nucleus of living cells: time of fluorescence recovery after photobleaching (FRAP) is an integrated measure of receptor function. Mol Med. 2004; 10(7-12): 80-8.
75. **Ferriman D, Gallwey J.** Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 83: 2694-2698.
76. **Marshall WA, Tanner JM.** Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969; 44(235): 291-303.
77. **Marshall WA, Tanner JM.** Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970; 45:13-24.
78. **Huizenga NA, de Lange P, Koper JW, de Herder WW, Abs R, Kasteren JH, de Jong FH, Lamberts SW.** Five patients with biochemical and/or clinical generalized glucocorticoid resistance without alterations in the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2000; 85(5): 2076-81.